Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P960040/S513

TELIGEN, ENERGEN, PUNCTUA, INCEPTA, ORIGEN, INOGEN, DYNAGEN, AUTOGEN, RESONATE, MOMENTUM, VIGILANT, PERCIVA

Boston Scientific · Decision date Jul 1, 2026

FDA DECISIONP960040/S513

What did the FDA approve?

FDA records P960040/S513 as a supplement to PMA P960040, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Jul 1, 2026.

FDA approval order statement

software changes for the LATITUDE NXT Patient Management System, Release 7.8
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Jul 1, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P960040/S513
Regulatory pathway
PMA supplement
Product code
LWS
Decision code
APPR
Decision date
Jul 1, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implantable cardioverter defibrillator (non-CRT).

Product code
LWS
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P960040/S509 · Related supplement

    VENTAK AV AICD VENTAK PRIZM DR/VR, VITALITY, COFIENT, AND TELIGEN AUTOMATIC IMPLANTABLE CARDIOVETER DEFIBRILLATOR SYSTEM

  2. P960040/S508 · Related supplement

    Implantable Cardioverter Defibrillator, INOGEN (Models D010, D011, D012, D013, D140, D141, D142, D143); DYNAGEN (Models

  3. P960040/S510 · Related supplement

    D010 INOGEN MINI ICD VR, D011 INOGEN MINI ICD VR, D012 INOGEN MINI ICD DR, D013 INOGEN MINI ICD DR, D020 DYNAGEN MI

  4. P960040/S511 · Related supplement

    D010 INOGEN MINI ICD VR,D011 INOGEN MINI ICD VR,D012 INOGEN MINI ICD DR,D013 INOGEN MINI ICD DR,D020 DYNAGEN MINI I

  5. P960040/S505 · Related supplement

    NG3 Implantable Cardioverter Defibrillators (ICDs): DYNAGEN Models: D020, D021, D022, D023, D150, D151, D152, D153; INOG

  6. P960040/S512 · Related supplement

    VENTAK AV AICD VENTAK PRIZM DR/VR, VITALITY, COFIENT, AND TELIGEN AUTOMATIC IMPLANTABLE CARDIOVETER DEFIBRILLATOR SYSTEM

  7. P960040/S513 received

    Application receipt date recorded by FDA.

  8. P960040/S507 · Related supplement

    Implantable Cardioverter Defibrillators (ICD) RESONATE: D420, D421, D432, D433, D520, D521, D532, D533; MOMENTUM: D120,

  9. P960040/S514 · Related supplement

    INOGEN, DYNAGEN, MOMENTUM, VIGILANT EL, PERCIVA MINI, RESONATE EL, PERCIVA HF, RESONATE HF

  10. P960040/S513 · FDA decision

    Real-Time Process

  11. P960040/S516 · Related supplement

    ICD INOGEN VR DF4 (D010); ICD INOGEN VR DF1/IS1 (D011); ICD INOGEN DR DF4/IS1 (D012); ICD INOGEN DR DF1/IS1 (D013);

Timeline entries are records held by MedtechLedger for P960040. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P960040

Product / regulatory recordCompanyPathwayDecision dateSource
Boston ScientificPMA supplementSep 16, 2025FDA
Boston ScientificPMA supplementSep 22, 2025FDA
Boston ScientificPMA supplementOct 22, 2025FDA
Boston ScientificPMA supplementOct 22, 2025FDA
Boston ScientificPMA supplementJan 8, 2026FDA
Boston ScientificPMA supplementApr 1, 2026FDA
Boston ScientificPMA supplementApr 21, 2026FDA
Boston ScientificPMA supplementJun 3, 2026FDA
Boston ScientificPMA supplementJul 23, 2026FDA
Boston ScientificPMA supplementAug 25, 2026FDA

Explore the linked device profile

Other records with product code LWS

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific

Headquarters
Not reported
FDA applicant address
4100 Hamline Ave. N, St Paul, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records